Rhythm Pharmaceuticals Stock Performance
| RYTM Stock | USD 102.53 4.46 4.55% |
Rhythm Pharmaceuticals has a performance score of 2 on a scale of 0 to 100. The company holds a Beta of 1.0, which implies possible diversification benefits within a given portfolio. Rhythm Pharmaceuticals returns are very sensitive to returns on the market. As the market goes up or down, Rhythm Pharmaceuticals is expected to follow. Rhythm Pharmaceuticals right now holds a risk of 3.29%. Please check Rhythm Pharmaceuticals maximum drawdown, skewness, as well as the relationship between the Skewness and day typical price , to decide if Rhythm Pharmaceuticals will be following its historical price patterns.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Rhythm Pharmaceuticals are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of very healthy basic indicators, Rhythm Pharmaceuticals is not utilizing all of its potentials. The recent stock price disarray, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return 4.55 | Five Day Return 3.15 | Year To Date Return (2.36) | Ten Year Return 241.77 | All Time Return 241.77 |
1 | Acquisition by Pamela Cramer of 10546 shares of Rhythm Pharmaceuticals at 6.8 subject to Rule 16b-3 | 11/18/2025 |
2 | Disposition of 3350 shares by Pamela Cramer of Rhythm Pharmaceuticals at 27.35 subject to Rule 16b-3 | 11/20/2025 |
3 | Guggenheim raises Rhythm Pharmaceuticals stock price target on promising PWS data - Investing.com Australia | 12/17/2025 |
4 | Acquisition by Pamela Cramer of 3350 shares of Rhythm Pharmaceuticals at 27.35 subject to Rule 16b-3 | 12/19/2025 |
5 | Rhythm Pharmaceuticals Trading Down 5.3 percent - Time to Sell - MarketBeat | 01/15/2026 |
6 | Zacks Research Downgrades Rhythm Pharmaceuticals to Strong Sell | 01/21/2026 |
7 | Analysts Set Rhythm Pharmaceuticals, Inc. Target Price at 131.29 | 01/26/2026 |
8 | Acquisition by Tetrault Lynn A. of 4712 shares of Rhythm Pharmaceuticals subject to Rule 16b-3 | 01/27/2026 |
9 | Federated Hermes Inc. Has 174.50 Million Position in Rhythm Pharmaceuticals, Inc. RYTM | 01/28/2026 |
10 | Disposition of 2343 shares by Pamela Cramer of Rhythm Pharmaceuticals subject to Rule 16b-3 | 01/30/2026 |
11 | Disposition of 9163 shares by Jennifer Lee of Rhythm Pharmaceuticals subject to Rule 16b-3 | 02/03/2026 |
12 | Disposition of 747 shares by Smith Hunter C of Rhythm Pharmaceuticals at 107.6654 subject to Rule 16b-3 | 02/04/2026 |
13 | Rhythm Pharmaceuticals, Inc. RYTM Shares Acquired by New York State Common Retirement Fund | 02/05/2026 |
14 | Disposition of 100 shares by Smith Hunter C of Rhythm Pharmaceuticals at 104.76 subject to Rule 16b-3 | 02/10/2026 |
15 | Acquisition by Smith Hunter C of 25000 shares of Rhythm Pharmaceuticals subject to Rule 16b-3 | 02/11/2026 |
16 | Disposition of 100 shares by Smith Hunter C of Rhythm Pharmaceuticals at 100.1 subject to Rule 16b-3 | 02/12/2026 |
17 | Assessing Rhythm Pharmaceuticals Valuation After Recent Share Price Weakness | 02/13/2026 |
18 | Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026 | 02/17/2026 |
| Begin Period Cash Flow | 60.4 M | |
| Total Cashflows From Investing Activities | -48.2 M |
Rhythm Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 10,066 in Rhythm Pharmaceuticals on November 20, 2025 and sell it today you would earn a total of 187.00 from holding Rhythm Pharmaceuticals or generate 1.86% return on investment over 90 days. Rhythm Pharmaceuticals is currently generating 0.0836% in daily expected returns and assumes 3.2879% risk (volatility on return distribution) over the 90 days horizon. In different words, 29% of stocks are less volatile than Rhythm, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Rhythm Pharmaceuticals Target Price Odds to finish over Current Price
The tendency of Rhythm Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 102.53 | 90 days | 102.53 | about 70.61 |
Based on a normal probability distribution, the odds of Rhythm Pharmaceuticals to move above the current price in 90 days from now is about 70.61 (This Rhythm Pharmaceuticals probability density function shows the probability of Rhythm Stock to fall within a particular range of prices over 90 days) .
Rhythm Pharmaceuticals Price Density |
| Price |
Predictive Modules for Rhythm Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Rhythm Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Rhythm Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Rhythm Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Rhythm Pharmaceuticals is not an exception. The market had few large corrections towards the Rhythm Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Rhythm Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Rhythm Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.04 | |
β | Beta against Dow Jones | 1.00 | |
σ | Overall volatility | 4.89 | |
Ir | Information ratio | 0.01 |
Rhythm Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Rhythm Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Rhythm Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Rhythm Pharmaceuticals had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 130.13 M. Net Loss for the year was (260.6 M) with profit before overhead, payroll, taxes, and interest of 155.86 M. | |
| Rhythm Pharmaceuticals currently holds about 235.6 M in cash with (113.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.64. | |
| Rhythm Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Candriam S.C.A. Grows Holdings in Revolution Medicines, Inc. RVMD |
Rhythm Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Rhythm Stock often depends not only on the future outlook of the current and potential Rhythm Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Rhythm Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 61 M | |
| Cash And Short Term Investments | 320.6 M |
Rhythm Pharmaceuticals Fundamentals Growth
Rhythm Stock prices reflect investors' perceptions of the future prospects and financial health of Rhythm Pharmaceuticals, and Rhythm Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Rhythm Stock performance.
| Return On Equity | -0.86 | ||||
| Return On Asset | -0.27 | ||||
| Profit Margin | (1.10) % | ||||
| Operating Margin | (1.03) % | ||||
| Current Valuation | 6.28 B | ||||
| Shares Outstanding | 66.74 M | ||||
| Price To Book | 44.00 X | ||||
| Price To Sales | 37.54 X | ||||
| Revenue | 130.13 M | ||||
| Gross Profit | 155.86 M | ||||
| EBITDA | (238.09 M) | ||||
| Net Income | (260.6 M) | ||||
| Cash And Equivalents | 235.6 M | ||||
| Cash Per Share | 4.64 X | ||||
| Total Debt | 3.94 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 5.59 X | ||||
| Book Value Per Share | 2.23 X | ||||
| Cash Flow From Operations | (113.88 M) | ||||
| Earnings Per Share | (3.10) X | ||||
| Market Capitalization | 6.54 B | ||||
| Total Asset | 392.27 M | ||||
| Retained Earnings | (1.16 B) | ||||
| Working Capital | 258.68 M | ||||
About Rhythm Pharmaceuticals Performance
By examining Rhythm Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Rhythm Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Rhythm Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 460.53 | 283.38 | |
| Return On Tangible Assets | (0.61) | (0.64) | |
| Return On Capital Employed | (1.10) | (1.05) | |
| Return On Assets | (0.60) | (0.63) | |
| Return On Equity | (1.82) | (1.73) |
Things to note about Rhythm Pharmaceuticals performance evaluation
Checking the ongoing alerts about Rhythm Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Rhythm Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Rhythm Pharmaceuticals had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 130.13 M. Net Loss for the year was (260.6 M) with profit before overhead, payroll, taxes, and interest of 155.86 M. | |
| Rhythm Pharmaceuticals currently holds about 235.6 M in cash with (113.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.64. | |
| Rhythm Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Candriam S.C.A. Grows Holdings in Revolution Medicines, Inc. RVMD |
- Analyzing Rhythm Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Rhythm Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Rhythm Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Rhythm Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Rhythm Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Rhythm Pharmaceuticals' stock. These opinions can provide insight into Rhythm Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rhythm Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Will Biotechnology sector continue expanding? Could Rhythm diversify its offerings? Factors like these will boost the valuation of Rhythm Pharmaceuticals. Anticipated expansion of Rhythm directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Rhythm Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (3.10) | Revenue Per Share | Quarterly Revenue Growth 0.543 | Return On Assets | Return On Equity |
The market value of Rhythm Pharmaceuticals is measured differently than its book value, which is the value of Rhythm that is recorded on the company's balance sheet. Investors also form their own opinion of Rhythm Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rhythm Pharmaceuticals' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Rhythm Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rhythm Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Rhythm Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Rhythm Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Rhythm Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.